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Abstract 
Review on ZAP70, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Identity 
Other names: SRK, STD, STCD, TZK, FLJ17670, 
FLJ17679 
HGNC (Hugo): ZAP70 
Location : 2q11.2 
DNA/RNA 
Description 
The ZAP70 gene encodes an enzyme belonging to 
the protein tyrosine kinase (PTK) family, and it plays 
a role in T-cell development and lymphocyte 
activation. The cDNA clone encoding human 
ZAP70 was identified for the first time by Chan et 
al. in 1992 (Chan 1992), and mouse cDNA for both 
ZAP70 and Syk was cloned two years later (Ku 
1994). Mutations in this gene cause selective T-cell 
defect, a severe combined immunodeficiency 
(SCID) disease characterized by a selective absence 
of CD8-positive T-cells (review in Wang 2010). 
Transcription 
The transcript encodes 619 amino acids with a mass 
of 69,872 Da. Three isoforms have been described 
(http://www.uniprot.org/uniprot/P43403#structure):  
Isoform 1 (full-length); Isoform 2 (1-307 is missing); 




ZAP70 is composed of two SH2 domains and a 
carboxy-terminal kinase domain (Fig. 1). The crystal 
structure of the tandem SH2 domains of the human 
PTK ZAP70 in complex with a peptide derived from 
the zeta-subunit of the T-cell receptor (TCR) was 
revealed by Hatada et al (Hatada 1995). A coiled coil 
of alpha-helices connects the two SH2 domains, 
producing an interface that constitutes one of the two 
critical phosphotyrosine binding sites, providing the 
molecular basis for highly selective association of 
ZAP70 with the T-cell receptor. 
The crystal structure of autoinhibited ZAP70 
revealed a new mechanism for maintaining an 
inactive kinase domain conformation (Deindl 2007), 
which also have been shown in cell-based 
experiments (Brdicka 2005; Deindl 2009). The two 
tandem SH2 domains that are separated by a linker 
region, termed interdomain A. Upon activation, 
conformational changes in ZAP70 promote 
disassembly of the interface mediating the 
autoinhibited conformation, and exposure of 
tyrosines Y292, Y315 and Y319 in interdomain B, 
leading to their phosphorylation that further 
destabilizes the interface (Wang 2010). 
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Figure 1. Schematic structure of inactive ZAP70 (adopted from Wang et al 2010). The ZAP70 domains indicated are the amino-





ZAP70 protein is expressed in all major thymocyte 
populations, with the level of expression being 
comparable to that found in both CD4+ and CD8+ 
peripheral T cells (Chan 1991;Irving 1993). 
Stimulation of the TCR results in tyrosine 
phosphorylation of a number of cellular substrates. 
One of these is the TCR zeta chain, which can 
mediate the transduction of extracellular stimuli into 
cellular effector functions. When ZAP70 was 
discovered, it represented a novel PTK and was 
found to be expressed in T cells and natural killer 
(NK) cells. The tyrosine phosphorylation and 
association of ZAP70 with TCR zeta was shown to 
require the presence of src family PTKs and provide 
a potential mechanism by which the src family PTKs 
and ZAP70 may interact to mediate TCR signal 
transduction (Chan 1991;Irving 1993). 
The first indication that ZAP70 may be expressed in 
the B cell lineage came from studies of B-cell 
chronic lymphocytic leukemia (CLL) (Rosenwald 
2001). ZAP70 was thereafter also reported to be 
expressed throughout B cell development at different 
maturational stages and that it plays a role in the 
transition of pro-B to pre-B cells in the bone marrow, 
a checkpoint controlled by signals from the pre-B 
cell receptor (pre-BCR), which monitors for 
successful rearrangement of immunoglobulin heavy 
chain genes (Schweighoffer 2003; Nolz 2005; 
Crespo 2006; Scielzo 2006). 
Localisation 
In the cytoplasmic compartment of the T-cell, once 
recruited to tyrosines in the immunoreceptor 
tyrosine-based activation motif (ITAM) of the TCR-
subunit, ZAP70 is activated by phosphorylation, at 
Tyr-493 in its activation loop, by Lck (Chan 1995; 
Wange 1995). Upon phosphorylation, these bound 
ZAP70 molecules autophosphorylate to create 
docking sites for SH2-domain-containing signalling 
proteins (Neumeister 1995; Katzav 1994; Couture 
1994; Duplay 1994). Docking of ZAP70 at the 
plasma membrane is required for its activation 
(reviewed in Fischer 2010). 
Function 
Indeed, PTKs play an integral role in T cell 
activation. TCR signal transduction and the events 
leading to activation of downstream signaling 
pathways involve many molecules, including the 
PTKs Src, Syk, Csk and Tec families, as well as 
adaptor proteins and effector enzymes in tyrosine 
phosphorylation cascades (review in Mustelin, 
2003). Both SH2-domains of ZAP70 are crucial for 
high avidity binding and for function in signal 
transduction (Bu 1995; review by Au-Yeung 2009 
and Wang 2010). ZAP70 is phosphorylated on 
tyrosine residues upon TCR stimulation, and 
functions in the initial step of TCR-mediated signal 
transduction in combination with the clustering of 
coreceptor (CD4 or CD8)-associated LCK with T 
cell receptors allows Lck to phosphorylate tyrosine 
residues in ITAMs in the intracellular tails of zeta 
chains of the TCR-complex (Yan 2013). Doubly 
phosphorylated ITAMs in the stimulated TCR 
complex recruit ZAP-70 to the plasma membrane. 
Activated ZAP70 subsequently phosphorylates at 
least two critically important adaptor proteins, linker 
for the activation of T cells (LAT) and SH2-domain-
containing leukocyte phosphoprotein of 76 kDa 
(SLP-76 ) (Bubeck Wardenburg 1996; Zhang 1998; 
Au-Yeung 2009). Interdomain B in the ZAP70 
molecule, between the C-terminal SH2-domain and 
the kinase domain, is also a critical region because 
of the three tyrosine residues Y292, Y315 and Y319 
that are phosphorylated by Lck upon TCR-triggering 
(Fischer 2010). The tyrosine Y292 binds the 
ubiquitin ligase c-Cbl and control both zeta (of the 
TCR-CD3-zeta complex) ubiquitination and TCR 
downmodulation, whereas Y315 interacts with the 
CT10 regulator of kinase II (CrkII ) adapter protein 
(Lupher 1997; Gelkop 1999; Fischer 2010). The 
tyrosine Y319 is also a binding site for PLC-gamma 
, resulting in a positive ZAP70 kinase-mediated 
regulation through PLC-gamma phosphorylation 
and Ca2+ mobilization (Di Bartolo 1999; Williams 
1999). The kinase domain itself also contains two 
tyrosine residues that are phosphorylated. 
Phosphorylation of Y493 by Src-family PTKs 
upregulate ZAP70 activity, whereas phosphorylation 
of Y492 seems to do the opposite, by negatively 
regulate ZAP70 kinase activity (Chan 1995; Wange 
1995). Moreover, the low molecular weight protein-
tyrosine phosphatase (LMPTP) specifically 
dephosphorylates the negative regulatory Tyr-292 of 
ZAP-70, thereby counteracting inactivation of 
ZAP70 (Bottini 2002). The proteins phosphorylated 
by ZAP70 are not that well investigated. VHR , a 
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Vaccinia virus VH-1 related dual-specific protein 
phosphatase that inactivates the mitogen-activated 
kinases Erk1 and Jnk, is phosphorylated at Y138 by 
ZAP70 (Alonso 2002). 
The role of ZAP70 in B cells has been investigated, 
but is poorly understood possibly due to the 
functional redundancy between Syk and ZAP70 
(Fallah-Arani 2008). Studies in CLL reveal that the 
ability of ZAP70 to enhance BCR signalling was 
independent of its kinase activity as both WT ZAP70 
and a catalytically inactive ZAP70 mutant induced 
similar increases in intracellular free Ca2+ 
concentration upon BCR triggering (Chen 2008). 
Homology 
Together with Syk, ZAP70 defines the Syk family of 
PTKs, with structural homology composed of non-
myristylated cytoplasmic peptides of two N-terminal 
Src-homology 2 (SH2) domains and a C-terminal 
catalytic domain (Taniguchi 1991; Chan 1992). 
Although Syk protein is also present in all thymocyte 
subsets, expression of Syk protein is down-regulated 
three- to fourfold in peripheral T cells. In contrast to 
ZAP70, expression of Syk is 12- to 15-fold higher in 
peripheral B cells when compared with peripheral T 
cells (Chan 1994a). Both ZAP-70 and Syk are 
dependent upon a Src-family protein tyrosine kinase 
for association with the phosphorylated zeta-chain. 
Thus, the differential expression of these kinases 
suggests the possibility of different roles for ZAP70 
and Syk in TCR signaling and thymic development 
(Palacios 2007). Another study showed functional 
homology in antigen receptor signaling by 
demonstrating that expression of ZAP70 in Syk- B 
cells reconstitutes BCR function (Kong 1995). 
Reconstitution required the presence of functional 
Src homology 2 (SH2) and catalytic domains of 
ZAP70. In addition, they demonstrated that both 
ZAP70 and Syk can bind directly to the 
phosphorylated Ig alpha and Ig beta subunits with 
affinities comparable to their binding to the TCR 
CD3 epsilon subunit (Kong 1995). Another feature 
that distinguish ZAP70 from Syk is its greater 
dependency on Src kinases for activation and its 
ability to phosphorylate and promote the auto-
activation of the downstream mitogen-activated 




ZAP70 base mutation registry for ZAP70 deficiency. 
ZAP70 deficiency is a rare autosomal recessive form 
of severe combined immunodeficiency characterized 
by the selective absence of CD8+ T cells and by 
abundant CD4+ T cells in the peripheral blood that 
are unresponsive to TCR-mediated stimuli in vitro 
(http://bioinf.uta.fi/ZAP70base/index.php). The first 
rare ZAP70 mutations in humans were discovered 
before mouse models were established. The rare 
ZAP70 mutations in humans have been described in 
about 20 patients from different families (Arpaia 
1994; Elder 1994; Chan 1994b; review in Fischer 
2010 and Karaca 2013). All patients that were 
reported with complete deficiency in ZAP70 activity 
presented with severe clinical phenotype similar to 
severe combined immunodeficiency. ZAP70 
mutations occurring in human SCID are mostly 
located in the kinase domain, but mutations causing 
transcriptional loss of ZAP70 or destabilization of 
the protein have also been reported. Elder et al 
reported that a patient with a missense mutation 
within the highly conserved DLAARN motif of the 
kinase domain (Elder 2001). Other examples are 
described by Fischer et al and by Karaca et al 
showing a lack or absence of CD8-positive T cells, 
high numbers of nonfunctional CD4-positive T cells, 
but normal numbers of B cells, with some patients 
having normal or elevated serum immunoglobulins 
(Ig) levels and defective antibody production 
(Matsuda 1999; Noraz 2000; Meinl 2000; Turul 
2009; Picard 2009; review in Fischer 2010 and 
Karaca 2013). 
Implicated in 
Severe combined immunodeficiency 
(SCID) 
Lack of ZAP70 in humans leads to a severe 
immunodeficiency characterized by the absence of 
CD8+ T-cells and TCR-unresponsive mature CD4+ 
T-cells. Mice lacking ZAP70 are also deficient in the 
production of CD4+ T-cells, while the natural killer 
cells are unaffected (Arpaia 1994; Elder 1994; Chan 
1994b; Negishi 1995; reviewed in Mustelin 2003).  
Roifman described in 1995 a new type of selective 
T-cell deficiency characterized by persistent 
infections reminiscent of severe combined 
immunodeficiency (Roifman 1995).  
The patients carry a mutation of ZAP70, resulting in 
a loss of the kinase activity.  
The study revealed that ZAP70 kinase appears to be 
indispensable for the development of CD8 single-
positive T cells as well as for the signal transduction 
and function of single-positive CD4 T cells.  
However, positive selection of CD4-positive T cells 
occurs in SCID patients, but the peripheral CD4-T 
cells do not respond normally to mitogens or to 
stimulation (Gelfand 1995).  
The result of ZAP70 mutations in humans leading to 
SCID have been described in the section above. 
Chronic lymphocytic leukemia  (CLL) 
ZAP70 was first thought to be uniquely expressed in 
T-cells, thymocytes and NK-cells. However, 
microarray analyses in CLL revealed that some B-
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cells expressed ZAP70 (Rosenwald 2001). CLL is 
characterized by a clonal expansion of neoplastic 
CD19+, CD5+, CD23+ B-cells in the blood, bone 
marrow, lymph nodes and spleen (Chiorazzi 2005). 
The heterogenous clinical course identifies two 
subsets of patients that includes the levels of CD38, 
the mutational status of immunoglobulin (Ig) heavy 
chain variable regions (VH) and cytogenetic 
abnormalities. Indeed, ZAP70 was found to be most 
discriminating gene between the two subsets of CLL, 
with higher expression of ZAP70 in the unmutated 
IgVH CLL group (Rosenwald 2001). Several studies 
validated this finding and reported that ZAP70 
predicted an unfavorable disease course in terms of 
disease progression and overall survival (Crespo 
2003; Orchard 2004; Wiestner 2003; and review in 
Rodrïguez-Vicente 2013; Rosenquist 2013), but 
discordant results exists (Kröber 2006). It was also 
shown that ZAP70 is a better predictor of the need 
for treatment than IgVH status (Rassenti 2004). 
Chen et al showed early that expression of ZAP70 is 
associated with increased B-cell receptor signaling 
in CLL (Chen 2002), but it seems like the presence 
of ZAP70 in CLL is independent of its kinase 
activity (Chen 2008), suggesting that the function is 
more likely as an adaptor molecule to facilitate BCR 
signaling in CLL, or may compete for a negative 
regulator of Syk (review in Au-Yeung 2009). 
Rassenti et al showed in 2008 that ZAP70 levels can 
be used as an independent marker of clinical 
outcome in CLL (Rassenti 2008).  The clinical 
course is correlated with augmented signaling down 
the BCR pathway, albeit not necessarily due to its 
enzymatic actions (Gobessi 2007; review in 
Chiorazzi 2012). It was also suggested that ZAP-70 
retards internalization of surface membrane IgM and 
CD79b from the cell membrane, leading to 
prolonged BCR pathway signaling.  An important 
component of ZAP-70 expression is indeed 
trafficking to solid tissue niches where signaling 
through chemokine receptors and BCRs might 
promote survival and further proliferation (Chiorazzi 
2012). Many research groups are now focusing on 
the microenvironment and, for instance the role of 
chemokines, in the disease progress of CLL (review 
in Burger 2014 and Ten hacken 2015). The major 
CLL compartments in humans are lymph nodes 
(LN), bone marrow (BM) and peripheral blood (PB), 
which are, in different ways, giving stimuli to the 
neoplastic B cells. Different cell types such as 
stromal cells, nurselike cells and lymphoma 
associated macrophages will interact in a complex 
cross-talk with CLL cells, together with T cells and 
NK cells (Burger 2014). These cells communicate 
with the CLL cells through an extensive network of 
adhesion molecules, chemokine receptors, tumor 
necrosis factor (TNF) family members, and soluble 
factors (Ten hacken 2015), resulting in either 
increased or decreased clonal growth and 
downstream intracellular signaling. 
Non-Hodgkin lymphoma 
ZAP70 is expressed in malignant non-Hodgkin 
lymphoma (NHL) B-cell subsets, including 
precursor B-cell acute lymphoblastic leukemia, 
diffuse large B-cell lymphoma, mantle cell 
lymphoma, multiple myeoloma, Hodgkin lymphoma 
and more(Sup 2004, Admirand 2004; Wang 2005; 
Carreras 2005; Scielzo 2006). 
B-cell acute lymphoblastic leukemia 
(B-ALL) 
ZAP-70 was consistently expressed and 
phosphorylated on Tyr319 in B-lineage ALL cells 
(Guillaume 2005). Crespo et al also found an 
expression of ZAP70 in 56% of B-ALL cases with 
pro/pre B cell phenotype (Crespo 2006), whereas 
childhood B-ALL showed even higher expression, in 
nine out of twelve cases (Wandroo 2008). In adult B-
ALL, both less and more frequent ZAP70 expression 
can be detected (Wang 2005; Chakupurakal 2012). 
Diffuse large B-cell lymphoma 
ZAP70 was expressed in a significantly higher 
percentage of tumor cells in the clinically more 
aggressive non-germinal center (GC) group 
compared with the prognostically favourable GC 
group (Fridberg 2007). 
Hodgkin lymphoma 
ZAP70 is expressed in rare cases of classic Hodgkin 
lymphoma (Sup 2004) whereas two other 
independent studies did not detect any ZAP70-
positive cells in Hodgkin lymphoma specimens 
(Admirand 2004; Carreras 2005). 
Anaplastic large cell lymphoma 
Anaplastic large cell lymphoma (ALCL) is a 
peripheral T cell lymphoma, often with defective 
expression of the TCR (Bonzheim 2004). Bonzheim 
et al showed that ZAP-70 was lacking in more than 
70% of all ALCL cases studied. Altogether, the lack 
of CD3 and ZAP70 contribute to the dysregulation 
of intracellular signaling pathways controlling T cell 
activation and survival. 
Rheumatoid arthritis 
B cells play an important role in the pathogenesis of 
rheumatoid arthritis(RA). It has been shown that 
ZAP70 expression in synovial fluid B cells obtained 
from RA patients was increased compared to SF B 
cells of osteoarthritis patients (Tolusso 2009). 
Moreover, B cell apoptosis studied in vitro showed 
that the ZAP70- B cells spontaneously undergoing 
apoptosis were significantly higher than ZAP70+ B 
cells. The authors concluded that the presence of 
ZAP70+ B cells increased survival and local 
inflammation in RA (Tolusso 2009). 
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